171.56
1.23%
-2.14
Dopo l'orario di chiusura:
171.60
0.04
+0.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$173.70
Aprire:
$172.88
Volume 24 ore:
6.73M
Relative Volume:
1.19
Capitalizzazione di mercato:
$303.17B
Reddito:
$55.53B
Utile/perdita netta:
$5.12B
Rapporto P/E:
59.57
EPS:
2.88
Flusso di cassa netto:
$15.62B
1 W Prestazione:
-2.06%
1M Prestazione:
-2.18%
6M Prestazione:
-2.12%
1 anno Prestazione:
+5.88%
Abbvie Inc Stock (ABBV) Company Profile
Nome
Abbvie Inc
Settore
Industria
Telefono
(847) 932-7900
Indirizzo
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Confronta ABBV con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
171.56 | 303.17B | 55.53B | 5.12B | 15.62B | 2.88 |
LLY
Lilly Eli Co
|
725.72 | 689.73B | 40.86B | 8.37B | -2.28B | 9.25 |
NVO
Novo Nordisk Adr
|
78.69 | 349.44B | 39.36B | 13.79B | 9.83B | 3.086 |
JNJ
Johnson Johnson
|
147.03 | 344.63B | 87.70B | 14.68B | 19.03B | 6.05 |
MRK
Merck Co Inc
|
97.92 | 251.88B | 63.17B | 12.15B | 14.84B | 4.77 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-12-10 | Ripresa | BofA Securities | Neutral |
2024-12-05 | Downgrade | Daiwa Securities | Outperform → Neutral |
2024-11-22 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
2024-11-15 | Iniziato | Wolfe Research | Outperform |
2024-11-04 | Aggiornamento | Argus | Hold → Buy |
2024-10-17 | Iniziato | Bernstein | Mkt Perform |
2024-06-05 | Aggiornamento | HSBC Securities | Hold → Buy |
2024-05-17 | Iniziato | Cantor Fitzgerald | Overweight |
2024-01-29 | Aggiornamento | William Blair | Mkt Perform → Outperform |
2023-12-18 | Downgrade | HSBC Securities | Buy → Hold |
2023-12-11 | Aggiornamento | Goldman | Neutral → Buy |
2023-11-09 | Iniziato | Deutsche Bank | Hold |
2023-10-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
2023-10-20 | Ripresa | UBS | Neutral |
2023-09-29 | Iniziato | Raymond James | Outperform |
2023-07-25 | Iniziato | William Blair | Mkt Perform |
2023-07-14 | Iniziato | HSBC Securities | Buy |
2023-04-05 | Downgrade | Argus | Buy → Hold |
2023-03-01 | Iniziato | Guggenheim | Buy |
2023-02-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
2023-02-10 | Aggiornamento | SVB Securities | Underperform → Market Perform |
2022-11-18 | Iniziato | Credit Suisse | Outperform |
2022-11-08 | Downgrade | Societe Generale | Buy → Hold |
2022-08-01 | Downgrade | Atlantic Equities | Overweight → Neutral |
2022-05-23 | Iniziato | SVB Leerink | Underperform |
2022-05-06 | Downgrade | Daiwa Securities | Outperform → Neutral |
2022-04-06 | Ripresa | Morgan Stanley | Overweight |
2022-02-28 | Downgrade | UBS | Buy → Neutral |
2022-02-03 | Reiterato | BMO Capital Markets | Outperform |
2022-02-03 | Reiterato | Barclays | Equal Weight |
2022-02-03 | Reiterato | BofA Securities | Neutral |
2022-02-03 | Reiterato | Goldman | Neutral |
2022-01-13 | Iniziato | Redburn | Buy |
2022-01-12 | Reiterato | BMO Capital Markets | Outperform |
2021-12-09 | Ripresa | Wells Fargo | Overweight |
2021-11-23 | Aggiornamento | Societe Generale | Hold → Buy |
2021-07-27 | Ripresa | Truist | Buy |
2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
2020-11-10 | Ripresa | Bernstein | Outperform |
2020-09-29 | Iniziato | Berenberg | Hold |
2020-06-23 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
2020-06-09 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
2020-06-02 | Aggiornamento | Argus | Hold → Buy |
2020-05-18 | Ripresa | BofA/Merrill | Neutral |
2020-05-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
2020-05-11 | Ripresa | Morgan Stanley | Overweight |
2020-04-20 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
2020-02-27 | Iniziato | Barclays | Equal Weight |
2020-02-06 | Iniziato | Mizuho | Buy |
2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
2019-12-26 | Reiterato | Cowen | Outperform |
2019-09-26 | Aggiornamento | Citigroup | Neutral → Buy |
2019-08-20 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
2019-06-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
2019-06-26 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
2019-05-28 | Iniziato | Goldman | Neutral |
2019-04-29 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
Mostra tutto
Abbvie Inc Borsa (ABBV) Ultime notizie
Pain Management Therapeutics Market Is Expected To Reach Revenue Of USD 120.7 Bn By 2033, At 3.9% CAGR: Dimension Market Research. - GlobeNewswire Inc.
AbbVie Inc. (ABBV): A Bull Case Theory - Insider Monkey
Diversify Advisory Services LLC Sells 6,472 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Artemis Investment Management LLP Has $85.98 Million Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Brady Martz Wealth Solutions LLC Takes Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Purchased by Ameritas Advisory Services LLC - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Bought by Wealth Alliance Advisory Group LLC - MarketBeat
Jackson Square Capital LLC Reduces Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Cohen Klingenstein LLC Reduces Stock Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Avanza Fonder AB Acquires Shares of 8,443 AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Short Interest Update - MarketBeat
Why Is AbbVie Inc. (ABBV) Among Louis Navellier’s Top Long-term Stock Picks? - Insider Monkey
AbbVie Inc. (NYSE:ABBV) Position Raised by Lake Street Private Wealth LLC - MarketBeat
AbbVie's SWOT analysis: stock outlook amid Humira erosion and pipeline growth - MSN
Brooklyn Investment Group Has $2.73 Million Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Householder Group Estate & Retirement Specialist LLC Reduces Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Wedge Capital Management L L P NC Trims Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Channel Wealth LLC Has $1.68 Million Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Purchased by Yarger Wealth Strategies LLC - MarketBeat
AbbVie Inc. (NYSE:ABBV) Stock Holdings Lifted by KMG Fiduciary Partners LLC - MarketBeat
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt - Benzinga
Two more AbbVie drugs put on the Medicare negotiation list - Crain's Chicago Business
AbbVie (ABBV) Benefitted from Top-Line Growth From Its Immunosuppressive Drugs - MSN
Decker Retirement Planning Inc. Purchases New Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie stock target cut, keeps Buy rating on growth outlook - Investing.com
FY2024 Earnings Forecast for AbbVie Issued By Zacks Research - MarketBeat
Tallon Kerry Patrick Buys New Shares in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Mason & Associates Inc Acquires 1,499 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Giant-Cell Arteritis Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA, ROA, and Developments | AbbVie, Novartis, CSL, Kiniksa Pharma, Eli Lilly, Roche, Johnson & Johnson, MorphoSys - Barchart
Why the Market Dipped But AbbVie (ABBV) Gained Today - Yahoo Finance
AbbVie Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
BMO maintains AbbVie stock Outperform rating - MSN
AbbVie's Quarterly Earnings Preview: What You Need to Know - Nasdaq
Humira Holds Firm at 72% Market Share-AbbVie Fends Off Biosimila - GuruFocus.com
AbbVie and Simcere Join Forces for Multiple Myeloma Breakthrough - Zenopa
Humira Holds Firm at 72% Market Share-AbbVie Fends Off Biosimilar Surge - Yahoo Finance
AbbVie retains Humira market share above 70%: report - MSN
AbbVie retains Humira market share amid biosimilars (ABBV:NYSE) - Seeking Alpha
JPM25 Day 3: AbbVie, Gilead, GSK and Dyne - BioSpace
JPM Day 3: AbbVie, Gilead, GSK and Dyne - PharmaLive
JPM25: The FDA’s future, AbbVie’s second thoughts and Lilly’s lesson - BioPharma Dive
Future Industry Growth Of Antiviral Drugs Market by 2024 To 2031 | AbbVie Inc., GSK plc, Dr. Reddy's - EIN News
AbbVie Inc. (NYSE:ABBV) Shares Purchased by BluePath Capital Management LLC - MarketBeat
Sawyer & Company Inc Sells 3,161 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Psoriasis Drugs Market Growth Drivers, Revenue, and Size - openPR
Wolff Wiese Magana LLC Acquires 1,750 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Meyer Handelman Co. Has $27.52 Million Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Radnor Capital Management LLC Has $4.38 Million Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie's Quarterly Earnings Preview: What You Need To Know - Barchart
The Zacks Analyst Blog Highlights Visa, AbbVie, Analog Devices and Precipio - Yahoo Finance
JP Morgan 2025: AbbVie counts on Skyrizi and Rinvoq to fill Humira-sized hole - Yahoo Finance
Abbvie Inc Azioni (ABBV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):